Jamal El-Mosleh, CEO Elicera Therapeutics

Towards new milestones – Elicera's plan for 2025 and 2026

Elicera Therapeutics Q1 report highlights promising initial clinical data from the CARMA study with ELC-301, stable patient recruitment and preparations for...

19th of May 2025
Anders Annexin

Annexin summarizes Q1: promising study data and fully subscribed issue

Annexin Pharmaceuticals has started 2025 with clear progress...

19th of May 2025
Clinical progress and capital injection strengthen Alzinova's Phase II plans

Clinical progress and capital injection strengthen Alzinova's Phase II plans

Alzinova started 2025 with clear progress in the development...

16th of May 2025

The Science Behind ColdZyme – Insights from Professors

A study with athletes has shown that Enzymaticas...

14th of May 2025

AI models analyze health data from 177 million patients

Researchers at University College London and King's College...

14th of May 2025
Breakthrough for Roche's new breast cancer treatment

Roche may reconsider $50 billion investment in the US

Swiss pharmaceutical giant Roche is considering reevaluating its...

13th of May 2025
RFKMore

Biosergen strengthens the board with an expert in anti-infective drugs

Biosergen, a biotechnology company focused on the development of...

12th of May 2025
Trump wants to cut drug prices by up to 80 percent

Trump wants to cut drug prices by up to 80 percent

President Donald Trump intends to sign an executive order...

12th of May 2025
Age Labs

Age Labs on the collaboration with Lipum: "We want to enable precision medicine in RA"

Lipum and Norwegian diagnostics company Age Labs collaborate to...

12th of May 2025
Biosergen takes aim at climate-driven fungal infections

Biosergen takes aim at climate-driven fungal infections

Research shows that climate change is driving the rapid...

9th of May 2025
Men

Mentice's CEO: "We anticipate a further ramp up in our sales"

Mentice reported strong growth in the first quarter...

9th of May 2025
BioInvent's BI-1808 gains broad FDA support

BioInvent receives FDA Fast Track Designation for BI-1808

BioInvent has published its interim report for Q1 2025,...

5th of May 2025

NEWSLETTER

You deserve the best!

Unlock our premium content: Become a subscriber!

Create Account

Tip the editors